Loading data for APGE — first visit, this takes a few seconds.
Apogee Therapeutics Inc
135.07 +135.07 (n/a)
- Capitalización de mercado
- $10.22B
- Volumen
- 0
- Próxima fecha de resultados
- Nov 9, 2026
Apogee Therapeutics Inc (APGE): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | — | n/a | n/a |
| EPS | — | n/a | n/a |
Métricas
- Precio de compra
- 96.59
- Ingresos (TTM)
- n/a
- Beneficio neto (TTM)
- -294M
- 0.33
- -4.34
- n/a
- -26
- P/B (TTM)
- 8.49
- P/S (TTM)
- n/a
- Fecha de resultados
- Nov 9, 2026
- Precio de venta
- 171.87
- Volumen
- 0
- Volumen medio (20D)
- 2,953,556
- Abierto
- 135.06
- Anterior Cerrar
- 0.00
- Rango del día
- 135.06 - 135.09
- Rango de 52 semanas
- 35.39 - 135.09
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Apogee Therapeutics Inc
Ver perfil →Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
Industria Biotechnology
Sector Healthcare
IPO Fecha Jul 17, 2026
Empleados 261
Bolsa de Valores NGM
Símbolo bursátil APGE
Sitio web https://www.apogeetherapeutics.com